key: cord-0937535-d22hgmok
authors: Yang, Tzu-Jing; Yu, Pei-Yu; Chang, Yuan-Chih; Liang, Kang-Hao; Tso, Hsian-Cheng; Ho, Meng-Ru; Chen, Wan-Yu; Lin, Hsiu-Ting; Wu, Han-Chung; Hsu, Shang-Te Danny
title: Impacts on the structure-function relationship of SARS-CoV-2 spike by B.1.1.7 mutations
date: 2021-05-12
journal: bioRxiv
DOI: 10.1101/2021.05.11.443686
sha: 524bd1d76736e7082a6c0dce671196b9ad2d69fe
doc_id: 937535
cord_uid: d22hgmok

The UK variant of the severe acute respiratory syndrome coronavirus (SARS-CoV-2), known as B.1.1.7, harbors several point mutations and deletions on the spike (s) protein, which potentially alter its structural epitopes to evade host immunity while enhancing host receptor binding. Here we report the cryo-EM structures of the S protein of B.1.1.7 in its apo form and in the receptor ACE2-bound form. One or two of the three receptor binding domains (RBDs) were in the open conformation but no fully closed form was observed. In the ACE-bound form, all three RBDs were engaged in receptor binding. The B.1.1.7-specific A570D mutation introduced a salt bridge switch that could modulate the opening and closing of the RBD. Furthermore, the N501Y mutation in the RBD introduced a favorable π-π interaction manifested in enhanced ACE2 binding affinity. The N501Y mutation abolished the neutralization activity of one of the three potent neutralizing antibodies (nAbs). Cryo-EM showed that the cocktail of other two nAbs simultaneously bound to all three RBDs. Furthermore, the nAb cocktail synergistically neutralized different SARS-CoV-2 pseudovirus strains, including the B.1.1.7.

salt bridge pairing that involves the A570D mutation. We propose that the switching of the A570D-mediated salt bridges may serve as the pedal of a pedal bin-like mechanism to modulate the RBD motion.

To glean structural insights into the receptor binding of S-UK, we determined the cryo-EM structure of S-UK in complex with the ectodomain of ACE2 fused to a super-fold green fluorescence protein (hereafter ACE2). The 3DVA analysis of the complex demonstrated that all three RBDs of S-UK were bound to ACE2 in a 3:3 stoichiometry as opposed to the previously reported heterogeneous binding stoichiometry between the S protein of the Wuhan variant (hereafter S-WT) and ACE2 ( Figure 3A -B and Supporting Information Fig. S3 ) 4, 24, 25 . Furthermore, the local orientation of the RBD in complex with ACE2 shows structurally dynamic, leading to the weak density and poor resolution (> 4.5 Å) of this region (Supporting Information Fig. S3 ).

To this end, we therefore carried out the local refinement with a mask focusing on the RBD and ACE2 to result in a density map of 3.5 Å (Supporting Information Fig. S3 ). The improved resolution of the region favors us to confidently build the atomic model to uncover the binding interface between RBD and ACE2. Detailed inspection revealed a newly formed p-p stacking between the mutated Y501 of S-UK and Y41 of ACE2, which could potentially provide additional stability of the complex formation ( Figure 3C ). Furthermore, a contracted rigid-body domain movement of ACE2 towards the RBD of S-UK relative to that of S-WT by 2.5 Å was observed (defined by the COM displacement of ACE2).

To evaluate the impact of the B.1.1.7-specific mutations on the binding of ACE2, we immobilized ACE2 onto the sensor tips for biolayer interferometry (BLI) and compared the binding kinetics to S-UK and S-D614G. A two-fold decrease of the dissociation constant (K d ) of S-UK (K d = 1.3 nM) compared to that of the D614G variant (K d = 3.1 nM) was observed ( Figure   3D ). The main difference was the reduced off-rate of S-UK (1.1x10 -4 s -1 ) compared to that of S-D614G (5.3x10 -5 s -1 ). Considering the slow dissociation kinetics of the binding event that could contribute to the uncertainty of the kinetic measurements, the effect of the N501Y mutation appeared to make marginal impact on the ACE2 binding kinetics.

In spite of the marginal difference in ACE2 binding, the mutations in S-UK could help SARS-CoV-2 evade neutralizing antibodies to achieve higher infectivity 13 . To address this issue, we tested the abilities of three chimeric anti-RBD antibodies (RBD-chAbs) to compete with ACE2 binding to S-UK. We recently demonstrated that the three RBD-chAbs, namely RBD-chAb15, 25 and 45, targeted three distinct sites within the RBM, that each of these RBD-chAbs potently neutralize pseudovirus of the original Wuhan strain of SARS-CoV-2, and that the cocktail of RBD-chAb25 and 45 can prophylactically protect mice and hamsters from SARS-CoV-2 infection 26 . BLI analysis showed that pre-incubation of S-D614G with each of the three RBD-chAbs effectively prevented ACE2 binding. However, RBD-chAb25 failed to compete ACE2 binding to S-UK while RBD-chAb15 and 45 remained highly effective ACE2 binding inhibitors ( Figure 4A -C). The loss of neutralizing activity of RBD-chAb25 against S-UK can be rationalized by the overlap of its structural epitope and the N501Y mutation evidenced by our recent cryo-EM analysis ( Figure 3C and Supporting Information Fig. S4 ). Instead, epitope mapping of RBD-chAb15 and 45 reside on two distal ends of RBM thus potentially allowing simultaneous binding to the same RBD. To verify our hypothesis, we sequentially mixed RBD-chAb45 and 15 with S-D614G shortly before cryo-EM grid vitrification, and determined the cryo-EM structure of the quaternary complex (S-D614G:RBD-chAb15/45). The resulting cryo-EM map revealed stoichiometric binding of RBD-chAb15 and 45 to all three RBDs, and the N501 was bypassed by the two RBD-chAbs ( Figure 4D -E). Despite the limited space above the three upward pointing RBDs to accommodate six antibodies, the poses of RBD binding by the two RBDs were essentially identical to that of individually bound cryo-EM structures, underscoring their potential to be used as a cocktail therapy for B.1.1.7.

To verify our hypothesis, we generated two pseudoviruses that individually expressed S-D614G and S-UK on the viral surface, and tested their pseudovirus neutralization activity of RBD-chAb15 and 45 in isolation and in combination (cocktail). The results showed that both nAbs were more effective against the D614G strain ( Figure 4J ) over the B.1.1.7 strain ( Figure   4K ), and that the cocktail of equal amounts of RBD-chAb15 and 45 was significantly more effective than the separately used nAbs.

In summary, we showed that the B.1.1.7-specific mutations minimally perturb the overall structure of the trimeric assembly of S-UK while a shift in the population of upward pointing RBD was observed. Compared to S-D614G, the two RBD-up population of S-UK was reduced without populating all RBD-down state. We identified a unique salt bridge switch involving the B.1.1.7specific A570D mutation with two lysine residues, K854 and K964, in the central helix to compensate the loss of the salt bridge between D614 and K854 due to the D614G mutation. We postulate that the newly evolved A570D mutation serves as a molecular switch in a pedal bin mechanism to kinetically modulate the up/down motion of RBD. The RBD-up state is stabilized by the double salt bridge -A570D-K854 and D571-K964 -thereby increasing the kinetic barrier for the RBD-up to return to the RBD-down state relative to S-D614G. A recent report shows that introducing the A570D mutation to S-D614G leads to increased sensitivity of three RBD-upspecific antibodies, thus leading support to our proposed regulatory mechanism achieved by the A570D mutation 13 . Furthermore, our S-UK:ACE2 structure adopts a 3:3 binding stoichiometry unlike previously reported cryo-EM structures of ACE2-bound S-WT, the majority of which display a single RBD-up engaged with ACE2 binding 4, 24, 25 . This serves as additional evidence to support our conjecture that the A570D mutation helps stabilize the RBD-up state.

Increased RBD-up population helps host receptor binding at the expenses of increased probability of being targeted by nAbs. The N501Y mutation in S-UK introduces p-p staking between N501Y and Y41 of ACE2, according to our cryo-EM structure of S-UK. This translates into increased binding affinity between S-UK and ACE2 compared to that between S-D614G and ACE2 according to our BLI measurements. In the context of antibody neutralizing, S-UK harbors the N501Y mutation within RBM to disrupt binding by a subset of neutralizing antibodies, including RBD-chAb25 in our case. Nevertheless, RBD-chAb15 and 45 remained highly neutralizing in the context of competing ACE2 binding ( Figure 4A -G). The quaternary cryo-EM structure of S-D614G:RBD-chAb15/45 showed that the two antibodies can simultaneously bind to the same RBD without contacting the N501Y mutation site. The pseudovirus assay further demonstrated that the combined use of RBD-chAb15 and 45 can synergistically neutralize pseudoviruses that correspond to D614G and B.1.1.7 ( Figure 4J -K).

RBD-chAb45 targets the tip of the RBM where F486 resides. Statistical analysis of reported SARS-CoV-2 S protein bound to convalescence plasma-derived nAbs indicated that F486 is one of the most targeted RBD residues ( Figure 4I ). The adjacent E484K mutation that is present in the emerging South African 501.v2 strain and the Brazilian P1 strain could potentially reduce the efficacy of RBD-chAb45. Several point mutations are also reported to be partially overlapping with the high-frequency nAb epitopes, which could impede their neutralizing activities ( Figure 4H ). Nevertheless, the structural epitope of RBD-chAb15 is less frequently recognized by convalescence plasma-derived nAbs and there is hitherto no mutation in the more transmissible emerging SARS-CoV-2 variants that are located within the epitope of RBD-chAb15 ( Figure 4G ). Therefore, the ability of RBD-chAb15 and 45 to simultaneously bind to distinct regions of RBD is therefore an attractive feature for considering their use in prophylactic cocktail antibody therapy to prevent mutational viral escape.

The codon-optimized nucleotide sequence of S-UK harboring the double proline mutations (2P, 986 KV 987 → 986 PP 987 ) and the furin cleavage site mutation (fm, 682 RRAR 685 → 682 GSAG 685 ) for stabilizing the S protein in a prefusion state 27 was a kind gift of Dr. Mi-Hua Tao (Institute of Biomedical Sciences, Academia Sinica). The DNA sequence corresponding the residues 1-1208 of S-UK was subcloned into the mammalian expression vector pcDNA3.4-TOPO (Invitrogen), which contains a foldon trimerization domain based on phage T4 fibritin followed by a c-myc epitope and a hexa-repeat histidine tag as described previously 28 . The same construct design was used for S-D614G as described elsewhere 23 .

The plasmids of S-D614G and S-UK were transiently transfected into HEK293 Freestyle cells for recombinant protein production as described previously 28 . The recombinant proteins were affinity purified by overnight binding to HisPur Cobalt Resin (Thermo Fisher Scientific, U. S. A.) in buffer A (50 mM Tris-HCl (pH 7.6), 300 mM NaCl, 5 mM imidazole and 0.02% NaN 3 at 4ºC), followed by washing with buffer B (50 mM Tris-HCl (pH 7.6), 300 mM NaCl, 10 mM imidazole), and elution by buffer C (50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 150 mM imidazole).

The eluted protein was further purified by size-exclusion chromatography (SEC) using a sizeexclusion column (Superose 6 increase 10/300 GL; GE Healthcare, U. S. A.) in TN buffer (50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 0.02 % NaN 3 ). The protein concentrations were determined by using the UV absorbance at 280 nm using an UV-Vis spectrometer (Nano-photometer N60, IMPLEN, Germany).

The sfGFP-ACE2 construct was obtained from Addgene (Plasmid #145171), which was deposited by Erik Proco (University of Illinois, USA) 29 . Recombinant sfGFP-ACE2 was transiently expressed in Expi293 cell and secreted into the culture medium. sfGFP-ACE2 was purified by an ion exchange column (HiTrap 5 ml Q FF anion exchange chromatography column; GE Healthcare, U. S. A.) eluted by a linear salt gradient from 10 to 1000 mM NaCl, followed by SEC using a size-exclusion column (Superdex 75 16/600 GL; GE Healthcare, U. S. A.) in TN buffer. The protein concentrations were determined by using the UV absorbance at 280 nm using an UV-Vis spectrometer (Nano-photometer N60, IMPLEN, Germany).

Three microliters of S-UK in 2.3 mg/ml was mixed with 1.2 equivalent of sfGFP-ACE2 (S-UK:sfGFP-ACE2) and incubated at room temperature for 1 hr before being separated by SEC using a size-exclusion column (Superose 6 increase 10/300 GL; GE Healthcare, U. S. A.) in TN buffer. The elution peak corresponding to S-UK in complex with sfGFP-ACE2 was collected and concentrated to 1.5 mg/ml for cryo-EM grid preparation.

Three microliters of S-D614G in 1.2 mg/ml was mixed with 1.2 equivalent of RBD-chAb45 and incubated at room temperature for 1 hr before being separated by SEC using a size-exclusion column (Superose 6 increase 10/300 GL; GE Healthcare, U. S. A.) in TN buffer. The elution peak corresponding to S-UK in complex with RBD-chAb45 was collected and concentrated to a total concentration of 1.5 mg/ml, followed by the addition of 1.2 equivalent RBD-chAb15 (S-UK:RBD-chAb15/45) for cryo-EM grid preparation. The preparation of RBD-chAb15 and 45 was described elsewhere 26 . 

All 2x binned super-resolution raw movies were subject to Relion-3.0 30 with dose-weighting and 5x5 patch-based alignment using GPU-based software MOTIONCOR2 31 . After motion correction, all corrected micrographs then were transferred to cryoSPARC v2.14 32 . Contrast transfer function (CTF) estimation was performed by patch-based CTF. The satisfied exposures, whose "CTF_fit_to_Res" parameters were between 2.5 and 4 Å, were selected and applied to particle picking. A small subset of micrographs was used for template-free blob picker. The picked particles were extracted with a box size of 384 pixels and followed by iterative rounds of 2D classification for filtering junk particles.

For S-UK, approximately 1.3 million particles were picked and classified by ab-initio reconstruction with C1 symmetry (class = 5), followed by heterogeneous refinement to generate five distinct classes (class = 5) and non-uniform refinement to generate an initial model. A mask was generated based on the initial 3D model for 3DVA by cryoSPARC v2 to generate five clusters of structural ensembles. Particle images corresponding to four of the five clusters were reextracted, un-binned, and non-uniformly refined with local CTF refinement to yield four cryo-EM maps with nominal resolutions ranging between 3.1 and 3.6 Å (Supporting Information Figure S1 ).

A similar imaging processing workflow was applied for S-UK:sfGFP-ACE2 and S-UK:RBD-chAb15/45. For S-UK:sfGFP-ACE2, five clusters of structural ensembles were also generated by 3DVA, but all particle images (n=463,191) were pooled and refined without symmetry constrain to yield a 3.3 Å cryo-EM map (Supporting Information Figure S3 ). The local resolution analysis was calculated using ResMap 33 . To improve the local resolution of ACE2 binding interface, a mask was created to include ACE2 and RBD for local refinement, which yielded a 3.5 Å cryo-EM of the subset of the S-UK:sfGFP-ACE2 structure. For S-UK:RBD-chAb15/45, approximately 2.3 million particles were picked for iterative 2D classification, which yield 78,790 particles for initial model building and templated particle picking, which generated 108,126 particles for 3D classification into three classes. The largest class (74%) was further refined by using a C3 symmetry to yield a 4.0 Å cryo-EM map (Supporting Information Figure S4 ). The local resolution analysis was calculated using ResMap 33 .

An initial model of S-UK was generated based on PDB ID: 6XM3 by using Swiss-Model 34 

A stock solution of sfGFP-ACE2 was diluted to at 10 µg/ml for immobilization onto High Precision Streptavidin (SAX) biosensors (Sartorius, Germany) in assay buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.02% NaN 3 , 0.1% BSA) according to manufacture instructions. Stock solutions of S-D614G and S-UK were serially diluted to 100, 50, 25, 12.5, 6.25 and 3.125 nM in assay buffer for independent binding using an OctetRED 96 biolayer interferometer (ForteBio, USA).

The association and dissociation were monitored over 600 s and 900 s, respectively. The six independent BLI sensorgrams with different S protein concentrations were baseline-corrected using double reference, i.e., biosensors without sfGFP-ACE2 were used to collect sensorgrams with another set of S protein samples to minimize non-specific binding and to extract the actual responses from the protein-protein interactions. The double reference subtracted data were globally fit to a 1:1 binding model using Data Analysis v10.0 software (ForteBio, USA). For RBD-chAb neutralization analysis, RBD-chAb15, 25 and 45 were individually mixed with an equal molar ratio of S-D614G or S-UK at a final concentration of 100 nM, and incubated at room temperature before BLI measurements using the same sfGFP-ACE2-immobilized biosensors with 400 s of association and 150 s of dissociation. The results were exported and replotted Prism 9 (GraphPad, USA).

The identification of structural epitopes of convalescent sera-derived RBD-specific nAbs at a residue-specific level as achieved by using the 'Protein interfaces, surfaces and assemblies' service PISA at the European Bioinformatics Institute (http://www.ebi.ac.uk/pdbe/prot_int/pistart.html) 40 . The list of cryo-EM and crystal structures of nAb-bound spike and RBD was manually curated by searching the entries deposited in the Protein Data Bank and their corresponding publications as tabulated in Tables S3-S4. The nAb contacting residues within RBD were defined by the function "Interfaces" of PISA and summarized in Table S5 . In cases where one RBD residue is in contact with both the heavy chain and a light chain of a given nAb, the epitope count was considered to be twice. The cumulated epitope counts were mapped onto the crystal structure of RBD in complex with ACE2

(PDB accession code 6M0J) and rendered by using Pymol (Schrodinger Inc. U. S. A.).

The pseudovirus neutralization assays were performed using 293T cells overexpressing ACE2

and pseudoviruses expressing full-length S protein provided by RNAi Core of Academic Sinica.

Four-fold serially dilution of chAbs were premixed with 1000 TU/well D614G, UK or SA strain of SARS-CoV-2 pseudovirus. The mixture was incubated for 1 h at 37°C and then added to preseeded 293T-ACE2 cells at 100 μl/well for 24 h at 37°C. The medium was removed and refilled with 100 μl/well DMEM for additional 48-h incubation. Next, 100 μl ONE-Glo™ luciferase reagent (Promega) was added to each well for 3-min incubation at 37°C. The luciferase activities were measured using a microplate spectrophotometer (Molecular Devices). The inhibition rate was calculated by comparing the luminescence value to the negative and positive control wells. IC50

was determined by a four-parameter logistic regression using GraphPad Prism (GraphPad Software Inc.).

Experimental materials and methods, including molecular cloning, protein expression and 

The supporting information includes:

Figures S1-S4, Table S1-S4 and references. 

Emergence of SARS-CoV-2 B.1.1.7 Lineage -United States

Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains

Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans

Structural and functional analysis of a potent sarbecovirus neutralizing antibody

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

Structural basis of receptor recognition by SARS-CoV-2

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Structural and Functional Analysis of the D614G SARS-CoV-2

D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction

The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2

Structural impact on SARS-CoV-2 spike protein by D614G substitution

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects

COVID-19 dominant D614G mutation in the SARS-CoV-2 spike protein desensitizes its temperature-dependent denaturation

Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM

A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent

Structure-guided Antibody Cocktail for Prevention and Treatment of COVID-19

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Cryo-EM analysis of a feline coronavirus spike protein reveals a unique structure and camouflaging glycans

Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2

New tools for automated high-resolution cryo-EM structure determination in RELION-3

MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy

cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination

Quantifying the local resolution of cryo-EM density maps

SWISS-MODEL: homology modelling of protein structures and complexes

UCSF Chimera--a visualization system for exploratory research and analysis

UCSF ChimeraX: Meeting modern challenges in visualization and analysis

PHENIX: a comprehensive Python-based system for macromolecular structure solution

MolProbity: all-atom structure validation for macromolecular crystallography

Inference of macromolecular assemblies from crystalline state